2-(bromomethyl)-4-(tert-butyl)-1,3-thiazol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(bromomethyl)-4-(tert-butyl)-1,3-thiazol
• 英文别名: 2-bromomethyl-4-tert-butylthiazole；2-(bromomethyl)-4-tert-butyl-1,3-thiazole
• 化学式: C₈H₁₂BrNS
• 分子量: 234.16
• InChiKey: TVKWECKQHNTPMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-羟基-5-甲氧基苯甲醛 、 2-(bromomethyl)-4-(tert-butyl)-1,3-thiazol 在 potassium carbonate 作用下， 以 乙酸乙酯 、 丙酮 、 甲苯 为溶剂， 生成 4-tert-butyl-2-(2-formyl-4-methoxyphenoxymethyl)thiazole
  参考文献：
  名称：

  Thiazolylbenzofuran derivatives and pharmaceutical composition

  摘要：

  式中R.sup.1、R.sup.2、R.sup.3、R.sup.4、A、X和Y的化合物：##STR1##及其药学上可接受的盐；具有作为白三烯和缓激反应物质（SRS-a）拮抗剂或抑制剂的活性，其制备方法，包括其的制药组合物，以及在人类或动物中在预防和/或治疗过敏或炎症方面的治疗方法。

  公开号：

  US05296495A1

文献信息

• Thiazolylbenzofuran derivatives and pharmaceutical compositions
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05994378A1

  公开（公告）日：1999-11-30

  This invention relates to novel thiazolylbenzofuran derivatives of formula (I) wherein R.sup.1 is lower alkyl, L is single bond or lower alkylene optionally substituted with aryl, oxo or hydroxy, and Q is a heterocyclic group optionally substituted with one or more suitable substituent(s); or lower alkoxy substituted with aryl which is substituted with one or more suitable substituent(s) and at least one of which is lower alkoxy optionally substituted with cyano, protected carboxy, carboxy, lower alkylene, a heterocyclic group optionally substituted with oxo, or amidino optionally substituted with hydroxy or lower alkoxy, or its salt, which possess activities as leukotriene and SRS-A antagonists or inhibitors.

  本发明涉及公式（I）的新型噻唑基苯并呋喃衍生物，其中R.sup.1是较低的烷基，L是单键或较低的烷基烯，可选地取代芳基，氧代或羟基，Q是一个杂环基团，可选地取代一个或多个合适的取代基；或者是取代芳基的较低烷氧基，该芳基取代一个或多个合适的取代基，其中至少一个是可选地取代氰基，保护羧基，羧基，较低的烷基烯，一个杂环基团，可选地取代氧代，或氨基甲酰，可选地取代羟基或较低的烷氧基，或其盐。该衍生物具有作为白三烯和SRS-A拮抗剂或抑制剂的活性。
• New thiazolylbenzofuran derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0528337A1

  公开（公告）日：1993-02-24

  A compound of the formula : wherein    R¹ is lower alkyl optionally substituted with halogen, lower alkylamino or lower alkyl(acyl)amino; cyclo(lower)alkyl; tricycloalkyl; aryl optionally substituted with lower alkoxy; or a heterocyclic group;    R² is hydrogen or halogen, or    R¹ and R² are taken together with the adjacent atoms to form cycloalken ring or an N-containing heterocyclic group optionally substituted with acyl,    R³ is hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy,    R⁴ is hydrogen; acyl; cyano; aryl optionally substituted with hydroxy(lower)alkyl, halo(lower)alkyl, cyano(lower)alkyl, heterocyclic(lower)alkyl or acyl; or lower alkyl which may be substituted with substituent(s) selected from the group consisting of halogen, cyano, hydroxy, lower alkylsulfonyloxy, arylsulfonyloxy, acyl, acyl(lower)alkylthio and aryl optionally substituted with halo(lower)alkyl, cyano(lower)alkyl, heterocyclic(lower)alkyl, cyano, acyl, acyl(lower)alkyl, a heterocyclic group or (lower alkylsulfinyl)(lower alkylthio)lower alkenyl;    A is lower alkylene, lower alkenylene or a single bond,    X is a single bond, O or S, and    Y is O or S, provided that A is loweralkylene or lower alkenylene, or       X is O or S when R¹ is lower alkyl or aryl and R² is hydorgen, and pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising them.

  式中的化合物： 其中 R¹ 是任选被卤素、低级烷基氨基或低级烷基（酰基）氨基取代的低级烷基；环（低级）烷基；三环烷基；任选被低级烷氧基取代的芳基；或杂环基团； R² 是氢或卤素，或 R¹ 和 R² 与相邻原子一起形成环烯环或可选择被酰基取代的含 N 杂环基团、 R³ 是氢、卤素、羟基、低级烷基或低级烷氧基、 R⁴ 是氢；酰基；氰基；可选择被羟基（低级）烷基、卤代（低级）烷基、氰基（低级）烷基、杂环（低级）烷基或酰基取代的芳基；或低级烷基，可被选自卤素、氰基、羟基、低级烷基磺酰氧基、芳基磺酰氧基、酰基、酰基（低级）烷硫基和任选被卤代（低级）烷基、氰基（低级）烷基、杂环（低级）烷基、氰基、酰基、酰基（低级）烷基、杂环基团或（低级烷基亚磺酰基）（低级烷硫基）低级烯基所取代的取代基所取代； A 是低级亚烷基、低级烯基或单键、 X 是单键、O 或 S，以及 Y 是 O 或 S、 只要 A 是低级亚烷基或低级烯基，或 当 R¹ 为低级烷基或芳基且 R² 为水合氢时，X 为 O 或 S、 及其药学上可接受的盐、制备工艺和包含它们的药物组合物。
• AZOLE DERIVATIVE
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0786457A1

  公开（公告）日：1997-07-30

  An azole derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof, having both of a leukotriene antagonistic effect and a thromboxane A2 antagonistic effect and being useful in preventing or treating allergic diseases, ischemic heart diseases or ischemic brain diseases, and a medicinal composition containing the same as the active ingredient, wherein R1 and R2 may be the same or different and represent each hydrogen, cycloalkyl, etc., or R1 and R2 together with (a) may form a fused ring (b) or (c) which may be substituted by optionally substituted lower alkyl, amino, etc.; R3, R6, R7, R8 may be the same or different and represent each hydrogen, amino, etc.; R4 represents cyano, tetrazolyl, -COOR9, etc.; R5 represents hydrogen or lower alkyl; D represents optionally substituted lower alkylene; X and Z may be the same or different and represent each oxygen or sulfur; Y represents -N= or -CH=; A represents -O-B-, -B-O-, -S-B-, -B-S- or -B-(B being lower alkylene or lower alkenylene); and n is 0, 1, or 2.

  一种通式(I)代表的唑衍生物或其药学上可接受的盐，具有白三烯拮抗作用和血栓素A2拮抗作用，可用于预防或治疗过敏性疾病、缺血性心脏病或缺血性脑疾病，以及一种以其为活性成分的药物组合物，其中R1和R2可以相同或不同，各自代表氢、环烷基等、或 R1 和 R2 与（a）一起可形成可被任选取代的低级烷基、氨基等取代的融合环（b）或（c）；R3、R6、R7、R8 可以相同或不同，各自代表氢、氨基等；R4 代表氰基、四唑基、-COOR9 等。R5 代表氢或低级烷基；D 代表任选取代的低级亚烷基；X 和 Z 可以相同或不同，各自代表氧或硫；Y 代表 -N= 或 -CH=；A 代表 -O-B-、-B-O-、-S-B-、-B-S- 或 -B-（B 为低级亚烷基或低级烯基）；n 为 0、1 或 2。
• Drug efflux pump inhibitor
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1652839A2

  公开（公告）日：2006-05-03

  A medicament for preventive and/or therapeutic treatment of a microbial infection having an activity of eliminating resistance of a microorganism with acquired resistance to an antimicrobial agent, which comprises as an active ingredient a compound represented by the following general formula (I), a physiologically acceptable salt thereof, or a hydrate thereof: wherein R1 and R2 independently represent hydrogen atom, a halogen atom, carboxyl group and the like; J1 represents a 5- or 6-membered heteroaromatic ring; W1 represents -CH=CH-, -C≡C-, -CH2CH2- and the like; A1 represents phenylene group, pyridinediyl group, furandiyl group and the like; G1 represents oxygen atom, carbonyl group, ethynyl group and the like; p represents an integer of from 0 to 3; G2 represents phenylene group, furandiyl group, tetrahydrofurandiyl group and the like; G3 represents -CH2- or single bond; m and n represent an integer of 0 or 1; and Q1 represents an acidic group.

  一种用于预防和/或治疗微生物感染的药物，具有消除对抗菌剂产生抗药性的微生物的抗药性的活性，其活性成分包括下式（I）所代表的化合物、其生理上可接受的盐或其水合物： 其中 R1 和 R2 分别代表氢原子、卤素原子、羧基等；J1 代表 5 或 6 元杂芳环；W1 代表 -CH=CH-、-C≡C-、-CH2CH2- 等；A1 代表亚苯基、吡啶二基、呋喃二基等；G1 代表氧原子、羰基、乙炔基等；p 代表 0 至 3 的整数；G2 代表亚苯基、呋喃二基、四氢呋喃二基等；G3 代表 -CH2- 或单键；m 和 n 代表 0 或 1 的整数；以及 Q1 代表酸性基团。
• DRUG DISCHARGE PUMP INHIBITORS
  申请人：Trine Pharmaceuticals, Inc.

  公开号：EP1227084B1

  公开（公告）日：2005-12-14